Microcap Ledger 4D Molecular Therapeutics, Inc. $FDMT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- Shares outstanding
- 49,778,127 [10-K 2024-02-29]
What the company doesAI summary of filing
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company developing genetic medicines using customized adeno-associated virus (AAV) vectors created through its proprietary Therapeutic Vector Evolution platform. The company's product candidates are designed to treat retinal diseases and cystic fibrosis lung disease by delivering therapeutic genes via intravitreal injection or aerosol delivery. Its lead program, 4D-150, is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema, with interim clinical data showing sustained visual acuity and reduced treatment burden compared to standard anti-VEGF therapy. The company is pre-revenue and generates no product sales, instead funding operations through capital raises and research collaborations, including partnerships with the Cystic Fibrosis Foundation and Otsuka Pharmaceutical. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $6.83M | −$141.70M | −$138.12M | $70.37M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $85.21M | −$140.11M | −$109.08M | $60.24M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $37.0K | −$160.87M | −$134.59M | $149.34M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$69.06M
- Cash runway Estimate
- ~3.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-11-02 | 42,753,607 | [10-Q 2023-11-09] |
| 2024-02-23 | 49,778,127 | [10-K 2024-02-29] |
- Shelf registration
- S-3 filed 2026-05-07; declared effective 2026-05-13 [S-3 2026-05-07]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Kirn David | sell | 58,061 | $12.92 | [4 2026-10-07] |
| 2026-10-05 | Kirn David | sell | 272 | $13.61 | [4 2026-10-07] |
| 2026-09-16 | Bizily Scott | exercise | 1,635 | $4.14 | [4 2026-09-22] |
| 2026-09-16 | Bizily Scott | sell | 1,635 | $13.65 | [4 2026-09-22] |
| 2026-09-14 | Kirn David | sell | 58,333 | $13.90 | [4 2026-09-16] |
| 2026-09-01 | Bizily Scott | exercise | 584 | $6.49 | [4 2026-09-03] |
| 2026-09-01 | Bizily Scott | sell | 584 | $14.00 | [4 2026-09-03] |
| 2026-08-19 | Kirn David | exercise | 50,000 | $4.14 | [4 2026-08-21] |
| 2026-08-19 | Kirn David | sell | 43,149 | $15.36 | [4 2026-08-21] |
| 2026-08-19 | Kirn David | sell | 25,927 | $16.42 | [4 2026-08-21] |
| 2026-08-17 | Bizily Scott | exercise | 1,635 | $4.14 | [4 2026-08-17] |
| 2026-08-17 | Bizily Scott | sell | 1,635 | $12.20 | [4 2026-08-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-20 | 8-K | Other events |
| 2026-06-29 | 8-K | Material agreement entered; New financial obligation |
| 2026-06-22 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | S-3 | Registration statement |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
Alerts for $FDMT
Email me when 4D Molecular Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.